These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22825352)

  • 21. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 22. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
    Olsson AG; Nilsson PM
    Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
    [No Abstract]   [Full Text] [Related]  

  • 23. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 24. CETP inhibition in perspective.
    Stock J
    Atherosclerosis; 2012 Feb; 220(2):325-8. PubMed ID: 22079329
    [No Abstract]   [Full Text] [Related]  

  • 25. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

  • 26. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
    Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P;
    N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
    Olsson AG
    Nutr Metab Cardiovasc Dis; 2010 Oct; 20(8):553-7. PubMed ID: 20739153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HALTS trial--halting atherosclerosis or halted too early?
    Blumenthal RS; Michos ED
    N Engl J Med; 2009 Nov; 361(22):2178-80. PubMed ID: 19915216
    [No Abstract]   [Full Text] [Related]  

  • 32. Illuminating HDL--is it still a viable therapeutic target?
    Rader DJ
    N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168
    [No Abstract]   [Full Text] [Related]  

  • 33. Is high HDL cholesterol always good?
    Olsson AG
    Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is raising HDL a futile strategy for atheroprotection?
    Joy T; Hegele RA
    Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy: raising HDL cholesterol levels: a flight of Icarus?
    Rossi GP; Rizzoni D
    Nat Rev Endocrinol; 2010 May; 6(5):245-6. PubMed ID: 20414314
    [No Abstract]   [Full Text] [Related]  

  • 40. Not so "good" cholesterol.
    Kritharides L
    BMJ; 2014 Jul; 349():g4664. PubMed ID: 25038076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.